ArticleJournal of clinical medicine2020
Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis.Frontiers in nutrition · 2022Pooled it
- The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- A high ratio of visceral fat area to psoas muscle area predicts poor overall survival for esophageal cancer patients receiving definitive chemoradiotherapy.Surgery today · 2026Article
- Effect of Preoperative Sarcopenic Obesity on Outcomes in Patients with Gastric Cancer After Surgery.Cancers · 2026Article
- Global trends in sarcopenia and cancer over the past 10 years: a bibliometric analysis.Discover oncology · 2025Article
- Artificial intelligence for body composition assessment focusing on sarcopenia.Scientific reports · 2025Article
- Article
- Prognostic impact of shift to low visceral fat mass after neoadjuvant chemotherapy in patients with esophageal cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- Sarcopenia, sarcopenic obesity and the clinical outcome of the older inpatients with COVID-19 infection: a prospective observational study.BMC geriatrics · 2024Observational
- Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy.Journal of cachexia, sarcopenia and muscle · 2024Article
- Nutritional Assessment Tools for Patients with Cancer: A Narrative Review.Current medical science · 2024Review
- Association between preoperative diagnosis of sarcopenia and postoperative pneumonia in resectable esophageal squamous cell carcinoma patients: a retrospective cohort study.Frontiers in oncology · 2023Article
- Recent Advances in Oral Squamous Cell Carcinoma.Journal of clinical medicine · 2022Article
- Management of elderly patients with esophageal squamous cell cancer.Japanese journal of clinical oncology · 2022Review
- Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.Journal of clinical medicine · 2022Article
- Supplemental parenteral nutrition in cancer care: why, who, when.Therapeutic advances in medical oncology · 2022Review
- The Prognostic Significance of Sarcopenia and the Neutrophil-to-Lymphocyte Ratio in Elderly Patients with Esophageal Squamous Cell Carcinoma.Cancer management and research · 2021Article
- Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the impact of body composition on clinical outcomes after neoadjuvant chemotherapy (NAC) followed by surgery for elderly cStage II/III esophageal squamous cell carcinoma (ESCC). Ninety-one patients ≥70 years old and 116 patients <70 years old with ECSS who underwent NAC between January 2013 and June 2018 at the Aichi Cancer Center were included. Body composition as assessed from computed tomography (CT), American Society of Anesthesiologists physical status (ASA-PS), and subjective global assessment (SGA) was assessed before initiation of NAC. Although elderly patients showed significantly poorer ASA-PS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.